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Remnant Cholesterol
“Non-(HDL-C  LDL-C)” as a
Coronary Artery Disease Risk Factor*
Ruth McPherson, MD, PHD
Ottawa, Ontario, Canada
In this issue the Journal, Varbo et al. (1) demonstrate that
irrespective of the fasting state, the cholesterol transported
by remnant lipoproteins is a robust predictor of coronary
artery disease (CAD) risk. Their findings provide clarifica-
tion to the debate regarding triglyceride-rich lipoproteins
and atherosclerosis (2). Overall, a consensus is emerging on
the basis of clinical and population data and genetic studies
that fasting and nonfasting plasma triglycerides are predic-
tive of both CAD and stroke risk, although the relationship
is attenuated after correction for associated variables, includ-
ing high-density lipoprotein cholesterol (HDL-C). How-
ever, triglycerides per se are not considered to be direct
culprits in the atherogenic process, hence the appropriate
focus in this report on the cholesterol component of
triglyceride-rich lipoproteins.
See page 427
Several population studies have demonstrated that non-
HDL-C, a measure of the cholesterol content of all apoli-
poprotein B (apo B)–containing lipoproteins (including
remnants), is a better marker of CAD risk than low-density
lipoprotein cholesterol (LDL-C) alone (3–5). Similarly
among statin-treated subjects, on-treatment levels of
LDL-C, non-HDL-C, and apo B were each associated
with risk for future major cardiovascular events, but the
strength of this association was greater for non-HDL-C
than for LDL-C or apo B, a marker of atherogenic particle
number rather than cholesterol content (6). The National
Cholesterol Education Program Adult Treatment Panel III
recommended non-HDL-C as a secondary target in pa-
tients with triglycerides 200 mg/dl (2.2 mmol/l) (7).
To specifically address the hypothesis that nonfasting
emnant cholesterol is causally related to coronary heart
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dnd grant T-7268 from the Heart & Stroke Foundation of Ontario.isease risk, blood samples were collected at various times
hroughout the day, the majority 1 to 5 h after a meal.
emnant cholesterol was calculated as total cholesterol 
DL-C  LDL-C, essentially non-(HDL-C  LDL-C).
s shown in Figure 3 in the paper, the observational hazard
atio (HR) for CAD was greater for subjects in the highest
ersus lowest quintile of remnant cholesterol (HR: 2.3; 95%
onfidence interval [CI]: 1.7 to 3.1) or remnant cholesterol/
DL-C (HR: 2.6; 95% CI: 2.1 to 3.2) compared with those
n the upper versus lower quintile of LDL-C (HR: 1.8; 95%
I: 1.4 to 2.2). This may not be surprising given that
emnant cholesterol levels displayed much greater variability
han did LDL-C. HDL-C was also strongly predictive of
AD risk, with an HR of 2.5 (95% CI: 2.1 to 3.0) for
ubjects in the lowest versus highest HDL-C quintile,
onsistent with other data (5).
The investigators then used Mendelian randomization to
upport a causative role for remnant cholesterol in CAD. To
o this, they chose a small number of single-nucleotide
olymorphisms (SNPs) shown to be strongly associated
ith each of remnant cholesterol, remnant cholesterol/
DL-C, LDL-C, and HDL-C. The notable findings were
hat the numbers of risk alleles for remnant cholesterol,
emnant cholesterol/HDL-C, and LDL-C were even more
trongly associated with CAD risk than measured lipid
evels. This observation concurs with data from previous
enetic studies (8,9) and likely relates to the fact that the
enetic determinants of a lipid trait are a more accurate
epresentation of a subject’s lifetime exposure compared
ith a single biochemical measure. In contrast, the number
f risk alleles for reduced HDL-C showed no relationship
o cardiovascular events.
The strength of the analysis includes the large datasets,
onsisting of over 73,000 Copenhagen subjects, enrolled in
of 2 prospective studies or a case-control study with a total
f 12,000 diagnosed with CAD. The results are plausible
iven that non-HDL-C is a robust marker of CAD risk (5).
he novel features of this analysis include the use of
onfasting lipid measurements and the focus on the non-
DL-C component of non-HDL-C.
A 9- to 12-h fast is the usual stipulation for plasma lipid
easurements. A nonfasting measurement would be more
onvenient for both patients and physicians and is already
he standard recommendation in Denmark. Although
lasma triglycerides vary considerably in the pre-prandial
ersus post-prandial state in subjects with even mild hyper-
riglyceridemia, this study demonstrates that there are rel-
tively small diurnal fluctuations in remnant cholesterol. Of
ote, the Emerging Risk Factors Collaboration also dem-
nstrated this, and that fasting status does not substantially
lter the relationship of plasma lipids and lipoproteins to
ardiovascular risk (5).
Varbo et al. (1) have exploited the principle of Mendelian
andomization to support their findings. Mendelian ran-
omization is based on the premise that because a genetic
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Remnant Cholesterol January 29, 2013:437–9variant is assigned randomly at birth, it is not susceptible to
confounding environmental factors. If such a variant selec-
tively influences a given trait and exhibits a concordant effect
on an outcome associated with the trait, it can be inferred
that the trait and outcome are causally related (10). How-
ver, a requirement for Mendelian randomization is lack of
leiotropy. A limitation of the present study is that some
leiotropic effects are evident for all 3 genes showing
ssociations with remnant cholesterol and coronary heart
isease risk. In large genomewide association studies,
RIB1 was also associated with LDL-C and HDL-C,
POA5 with HDL-C and LDL-C (8), and GCKR (encod-
ng the glucokinase receptor) with fasting glucose and
iabetes risk (11).
Another limitation of this Mendelian randomization
tudy is that the analyses were confined to a small number of
NPs and genes, including 3 SNPs (TRIB1, GCKR, and
APOA5) for remnant cholesterol; 4 SNPs in a single gene,
lipoprotein lipase (LPL) for “remnant cholesterol and
HDL-C”; SNPs in 2 genes, ABCA1 and LIPC (encoding
hepatic lipase) for HDL-C; and SNPs in 3 genes (LDLR,
APOB, and PCSK9) for LDL-C. Because different biolog-
ical pathways lead to variability in these lipid fractions, the
interpretation of the results should be limited to the
processes regulated by the genes included in the analysis.
Consistent with the present findings, previous large Men-
delian randomization studies have not supported a casual
relationship between common genetic variants associated
Figure 1 Remnant Cholesterol and Atherosclerosis
Triglyceride (TG)–rich lipoproteins (LPs) containing a single molecule of apolipoprot
lipase (LPL) on the surface of endothelial cells. Lipolysis of TG-rich LPs by LPL yiel
more cholesterol per particle than low-density LP (LDL) and can cross the endothe
fashion by scavenger receptors expressed by resident macrophages in the subendwith HDL-C (near ABCA1, LCAT, LIPC, or LIPG) andcardiovascular disease (12,13), but it remains possible that
SNPs altering expression or function of other genes in the
HDL synthesis pathway such as APOA1 might associate
with altered CAD risk (14).
Importantly from a clinical point of view, there is abun-
dant evidence that remnant lipoproteins are atherogenic.
Remnants are known to cross the endothelial barrier (15)
and have been identified in human arteries. Because of their
larger size, they carry 5 to 20 times as much cholesterol per
particle as LDL. Importantly, unlike native LDL, remnants can
be taken up in an unregulated fashion by scavenger receptors
expressed by resident macrophages in the subendothelial space
(16), thus promoting foam cell formation (Fig. 1). What is clear
from the study of Varbo et al. (1) is that irrespective of the fasting
state, remnant cholesterol is an important component of “non-
HDL-C” and a risk factor for CAD.
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